About The Study: This study found a profound decrease in the utilization of metabolic bariatric surgery, with a 34.1% decrease from 2022 to 2024, while glucagon-like peptide-1 receptor agonist (GLP-1) use increased by 140.4% over the same period. Given the year-on year declines in metabolic bariatric surgery utilization, these trends may continue given the persistent and growing prescribing of GLP-1s.
Corresponding Author: To contact the corresponding author, Robert J. Calzaretta Jr, MIDS, email robert.calzaretta@analysisgroup.com .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamasurg.2026.1343)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/jamasurg.2026.1343?guestAccessKey=bf60d8c4-391f-4322-bfd4-8bc3a52a068a&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051326
JAMA Surgery